Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Edison Pharmaceuticals' 28-day Phase 2A double-blind placebo-controlled clinical trial evaluating EPI-A0001 has failed to demonstrate improvement of glucose disposition index (a measure of glucose handling by the body) in patients with Friedreich's ataxia.
Subscribe to our email newsletter
The trial evaluated patients who were divided into three arms: placebo, low dose and high dose EPI-A0001.
In the trial, EPI-A0001 improved neurological function as assessed by the Friedreich’s Ataxia Rating Scale (FARS).
The improvement in the FARS was significant in both the high and low dose groups in comparison to placebo.
The US Food and Drug Administration has given orphan drug status to EPI-A0001.